Alcon AG (ALC)vsHarvard Bioscience Inc (HBIO)
ALC
Alcon AG
$66.03
-0.78%
HEALTHCARE · Cap: $34.08B
HBIO
Harvard Bioscience Inc
$8.03
-1.47%
HEALTHCARE · Cap: $37.33M
Smart Verdict
WallStSmart Research — data-driven comparison
Alcon AG generates 12269% more annual revenue ($10.86B vs $87.81M). ALC leads profitability with a 5.9% profit margin vs -11.9%. ALC appears more attractively valued with a PEG of 1.27. ALC earns a higher WallStSmart Score of 51/100 (C-).
ALC
Buy51
out of 100
Grade: C-
HBIO
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.0%
Fair Value
$65.08
Current Price
$66.03
$0.95 premium
Intrinsic value data unavailable for HBIO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
ROE of 3.8% — below average capital efficiency
5.9% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Weak financial health signals
ROE of -147.1% — below average capital efficiency
Earnings declined 80.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALC
The strongest argument for ALC centers on Price/Book, Debt/Equity. PEG of 1.27 suggests the stock is reasonably priced for its growth.
Bull Case : HBIO
Revenue growth of 11.1% demonstrates continued momentum. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bear Case : ALC
The primary concerns for ALC are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 53.8x leaves little room for execution misses.
Bear Case : HBIO
The primary concerns for HBIO are Market Cap, Piotroski F-Score, Return on Equity. Debt-to-equity of 5.96 is elevated, increasing financial risk.
Key Dynamics to Monitor
ALC profiles as a value stock while HBIO is a turnaround play — different risk/reward profiles.
HBIO carries more volatility with a beta of 1.49 — expect wider price swings.
HBIO is growing revenue faster at 11.1% — sustainability is the question.
ALC generates stronger free cash flow (414M), providing more financial flexibility.
Bottom Line
ALC scores higher overall (51/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alcon AG
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.
Visit Website →Harvard Bioscience Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?